eISSN: 2084-9885
ISSN: 1896-6764
Neuropsychiatria i Neuropsychologia/Neuropsychiatry and Neuropsychology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
1/2006
vol. 1
 
Share:
Send email
Share:
abstract:

Review article
Pharmacogenomics of antidepressants

Joanna Hauser

Neuropsychiatria i Neuropsychologia 2006; 1, 1: 43–48
Online publish date: 2006/11/27
View full text Get citation
 
Genetic factors are believed to play a major role in the variation of treatment response and the incidence of adverse effects of medications. Pharmacogenetics is concerned with the role of genetic factors in predicting drug response and adverse effects. This requires some knowledge of either the drug’s pharmacokinetic or pharmacodynamic profile so that candidate genes can be studied. Considering the hypothesis for the mechanism of action of antidepressants, most pharmacogenetic studies have concentrated on polymorphisms in genes involved in the serotonergic and noradrenergic system. Many studies have reported an association between the response to SSRI and 5-HTTLPR polymorphism. The aim of pharmacogenomic is to study the relationship between whole genome factors including the expressed transcriptome and proteome and drug response. It is hoped that pharmacogenomic studies will lead to the prediction of response to antidepressants and reduction of adverse effects.
keywords:

temperament, 5-HTT, DAT1, DRD4, polymorphism
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.